Viking gets commercial chief while other obesity biotechs sell; Novo's Uli Stilz steps down

→ As Viking Therapeutics shareholders wait with poorly-concealed impatience for a buyer to emerge, the obesity and MASH-focused biotech has appointed a new chief commercial officer. ...